{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T19:52:56Z","timestamp":1724874776356},"reference-count":32,"publisher":"Baishideng Publishing Group Inc.","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["WJG"],"published-print":{"date-parts":[[2008]]},"DOI":"10.3748\/wjg.14.1908","type":"journal-article","created":{"date-parts":[[2008,3,28]],"date-time":"2008-03-28T03:42:12Z","timestamp":1206675732000},"page":"1908","source":"Crossref","is-referenced-by-count":5,"title":["Hemodynamic effects of propranolol with spironolactone in patients with variceal bleeds: A randomized controlled trial"],"prefix":"10.3748","volume":"14","author":[{"given":"Binay K","family":"De","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deep","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rimi","family":"Som","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pranab K","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Subrata K","family":"Pal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anirban","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2060","reference":[{"key":"ref1","unstructured":"Burroughs AK, Bosch J. Clinical manifestations and management of bleeding episodes in cirrhotics. Oxford text book of clinical Hepatology Oxford: Oxford University Press; 1991;408-425."},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Burroughs AK, McCormick PA. Natural history and prognosis of variceal bleeding. Baillieres Clin Gastroenterol 1992;6:437-450.","DOI":"10.1016\/0950-3528(92)90031-9"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Poynard T, Cales P, Pasta L, Ideo G, Pascal JP, Pagliaro L, Lebrec D. Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. An analysis of data and prognostic factors in 589 patients from four randomized clinical trials. Franco-Italian Multicenter Study Group. N Engl J Med 1991;324:1532-1538.","DOI":"10.1056\/NEJM199105303242202"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Groszmann RJ, Bosch J, Grace ND, Conn HO, Garcia-Tsao G, Navasa M, Alberts J, Rodes J, Fischer R, Bermann M. Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. Gastroenterology 1990;99:1401-1407.","DOI":"10.1016\/0016-5085(90)91168-6"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Feu F, Garcia-Pagan JC, Bosch J, Luca A, Teres J, Escorsell A, Rodes J. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. Lancet 1995;346:1056-1059.","DOI":"10.1016\/S0140-6736(95)91740-3"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Vorobioff J, Picabea E, Villavicencio R, Puccini V, Rossi O, Bordato J, Audano M. Acute and chronic hemodynamic effects of propranolol in unselected cirrhotic patients. Hepatology 1987;7:648-653.","DOI":"10.1002\/hep.1840070406"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Gournay J, Masliah C, Martin T, Perrin D, Galmiche JP. Isosorbide mononitrate and propranolol compared with propranolol alone for the prevention of variceal rebleeding. Hepatology 2000;31:1239-1245.","DOI":"10.1053\/jhep.2000.8106"},{"key":"ref8","unstructured":"Okumura H, Aramaki T, Katsuta Y, Satomura K, Akaike M, Sekiyama T, Terada H, Ohsuga M, Komeichi H, Tsutsui H. Reduction in hepatic venous pressure gradient as a consequence of volume contraction due to chronic administration of spironolactone in patients with cirrhosis and no ascites. Am J Gastroenterol 1991;86:46-52."},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Garcia-Pagan JC, Salmeron JM, Feu F, Luca A, Gines P, Pizcueta P, Claria J, Piera C, Arroyo V, Bosch J. Effects of low-sodium diet and spironolactone on portal pressure in patients with compensated cirrhosis. Hepatology 1994;19:1095-1099.","DOI":"10.1002\/hep.1840190506"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Sugano S, Kawafune T, Okajima T, Ishii K, Watanabe M, Takamura N. Chronic splanchnic hemodynamic effects of spironolactone with unrestricted sodium diet in patients with compensated cirrhosis. Dig Dis Sci 1998;43:893-897.","DOI":"10.1023\/A:1018851022316"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Nevens F, Lijnen P, VanBilloen H, Fevery J. The effect of long-term treatment with spironolactone on variceal pressure in patients with portal hypertension without ascites. Hepatology 1996;23:1047-1052.","DOI":"10.1002\/hep.510230517"},{"key":"ref12","unstructured":"Sen S, De BK, Biswas PK, Biswas J, Das D, Maity AK. Hemodynamic effect of spironolactone in liver cirrhosis and propranolol-resistant portal hypertension. Indian J Gastroenterol 2002;21:145-148."},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Japanese Research society for portal hypertension general rules for recording endoscopic findings of esophageal varices. Jpn J Surg 1980;10:84-87.","DOI":"10.1007\/BF02468653"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Groszmann RJ, Glickman M, Blei AT, Storer E, Conn HO. Wedged and free hepatic venous pressure measured with a balloon catheter. Gastroenterology 1979;76:253-258.","DOI":"10.1016\/0016-5085(79)90330-5"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Kravetz D, Sikuler E, Groszmann RJ. Splanchnic and systemic hemodynamics in portal hypertensive rats during hemorrhage and blood volume restitution. Gastroenterology 1986;90:1232-1240.","DOI":"10.1016\/0016-5085(86)90390-2"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Colombato LA, Albillos A, Groszmann RJ. Temporal relationship of peripheral vasodilatation, plasma volume expansion and the hyperdynamic circulatory state in portal-hypertensive rats. Hepatology 1992;15:323-328.","DOI":"10.1002\/hep.1840150224"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Garcia-Pagan JC, Escorsell A, Moitinho E, Bosch J. Influence of pharmacological agents on portal hemodynamics: basis for its use in the treatment of portal hypertension. Semin Liver Dis 1999;19:427-438.","DOI":"10.1055\/s-2007-1007130"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Sugano S, Suzuki T, Nishio M, Makino H, Okajima T. Chronic splanchnic hemodynamic effects of low-dose transdermal nitroglycerin versus low-dose transdermal nitroglycerin plus spironolactone in patients with cirrhosis. Dig Dis Sci 1997;42:529-535.","DOI":"10.1023\/A:1012993224326"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Abecasis R, Kravetz D, Fassio E, Ameigeiras B, Garcia D, Isla R, Landeira G, Dominguez N, Romero G, Argonz J. Nadolol plus spironolactone in the prophylaxis of first variceal bleed in nonascitic cirrhotic patients: A preliminary study. Hepatology 2003;37:359-365.","DOI":"10.1053\/jhep.2003.50032"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Abraldes JG, Tarantino I, Turnes J, Garcia-Pagan JC, Rodes J, Bosch J. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology 2003;37:902-908.","DOI":"10.1053\/jhep.2003.50133"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Bureau C, Peron JM, Alric L, Morales J, Sanchez J, Barange K, Payen JL, Vinel JP. \"A La Carte\" treatment of portal hypertension: Adapting medical therapy to hemodynamic response for the prevention of bleeding. Hepatology 2002;36:1361-1366.","DOI":"10.1002\/hep.1840360611"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Villanueva C, Balanzo J, Novella MT, Soriano G, Sainz S, Torras X, Cusso X, Guarner C, Vilardell F. Nadolol plus isosorbide mononitrate compared with sclerotherapy for the prevention of variceal rebleeding. N Engl J Med 1996;334:1624-1629.","DOI":"10.1056\/NEJM199606203342502"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Villanueva C, Minana J, Ortiz J, Gallego A, Soriano G, Torras X, Sainz S, Boadas J, Cusso X, Guarner C. Endoscopic ligation compared with combined treatment with nadolol and isosorbide mononitrate to prevent recurrent variceal bleeding. N Engl J Med 2001;345:647-655.","DOI":"10.1056\/NEJMoa003223"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Patch D, Sabin CA, Goulis J, Gerunda G, Greenslade L, Merkel C, Burroughs AK. A randomized, controlled trial of medical therapy versus endoscopic ligation for the prevention of variceal rebleeding in patients with cirrhosis. Gastroenterology 2002;123:1013-1019.","DOI":"10.1053\/gast.2002.35955"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"McCormick PA, Patch D, Greenslade L, Chin J, McIntyre N, Burroughs AK. Clinical vs haemodynamic response to drugs in portal hypertension. J Hepatol 1998;28:1015-1019.","DOI":"10.1016\/S0168-8278(98)80351-6"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Villanueva C, Lopez-Balaguer JM, Aracil C, Kolle L, Gonzalez B, Minana J, Soriano G, Guarner C, Balanzo J. Maintenance of hemodynamic response to treatment for portal hypertension and influence on complications of cirrhosis. J Hepatol 2004;40:757-765.","DOI":"10.1016\/j.jhep.2004.01.017"},{"key":"ref27","unstructured":"Groszmann RJ, de Franchis R. Portal Hypertension. Schiff’s Diseases of the liver Philadelphia: Lipincott-Raven; 1999;394."},{"key":"ref28","unstructured":"Bosch J, D’Amico G, Garcia-Pagan JC. Portal hypertension and nonsurgical management. Schiff’s Diseases Of The Liver. 10th ed Lippincott: Williams & Wilkins; 2007;436."},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Oberleithner H, Riethmuller C, Ludwig T, Hausberg M, Schillers H. Aldosterone remodels human endothelium. Acta Physiol (Oxf) 2006;187:305-312.","DOI":"10.1111\/j.1748-1716.2006.01574.x"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Fujisawa G, Muto S, Okada K, Kusano E, Ishibashi S. Mineralocorticoid receptor antagonist spironolactone prevents pig serum-induced hepatic fibrosis in rats. Transl Res 2006;148:149-156.","DOI":"10.1016\/j.trsl.2006.03.007"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Sonder SU, Woetmann A, Odum N, Bendtzen K. Spironolactone induces apoptosis and inhibits NF-kappaB independent of the mineralocorticoid receptor. Apoptosis 2006;11:2159-2165.","DOI":"10.1007\/s10495-006-0286-3"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Hillebrand U, Schillers H, Riethmuller C, Stock C, Wilhelmi M, Oberleithner H, Hausberg M. Dose-dependent endothelial cell growth and stiffening by aldosterone: endothelial protection by eplerenone. J Hypertens 2007;25:639-647.","DOI":"10.1097\/HJH.0b013e328013f492"}],"container-title":["World Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.wjgnet.com\/1007-9327\/full\/v14\/i12\/1908.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,9]],"date-time":"2019-05-09T16:23:56Z","timestamp":1557419036000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.wjgnet.com\/1007-9327\/full\/v14\/i12\/1908.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008]]},"references-count":32,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.3748\/wjg.14.1908","relation":{},"ISSN":["1007-9327"],"issn-type":[{"value":"1007-9327","type":"print"}],"subject":[],"published":{"date-parts":[[2008]]}}}